Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KONCERT once-daily vs twice-daily lopinavir/ritonavir in paediatric HIV
2009-013648-35Phase 2Completed
- Sponsor
- Penta Foundation
- Start
- Mar 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of lopinavir + ritonavir in human immunodeficiency virus infection (HIV) (2 arms), sponsored by Penta Foundation. Primary endpoint: Virologic failure (HIV-1 RNA ≥50 copies/ml). Started Mar 2010; status: completed.
02
Drugs
lopinavir + ritonavir
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on 2009-013648-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013648-35.